Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis
- ,
- Catherine E. Terrell,
- Scott H. Millen,
- Jonathan D. Katz,
- David A. Hildeman,
- Michael B. Jordan(corresponding author)
- ,
- University of Cincinnati
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOpen access
Abstract
<p>Hemophagocytic lymphohistiocytosis (HLH) is an inborn disorder of immune regulation caused by mutations affecting perforindependent cytotoxicity. Defects in this pathway impair negative feedback between cytotoxic lymphocytes and APCs, leading to prolonged and pathologic activation of T cells. Etoposide, a widely used chemotherapeutic drug that inhibits topoisomerase II, is the mainstay of treatment for HLH, although its therapeutic mechanism remains unknown. We used a murine model of HLH, involving lymphocytic choriomeningitis virus infection of perforin-deficient mice, to study the activity and mechanism of etoposide for treating HLH and found that it substantially alleviated all symptoms of murine HLH and allowed prolonged survival. This therapeutic effect was relatively unique among chemotherapeutic agents tested, suggesting distinctive effects on the immune response. We found that the therapeutic mechanism of etoposide in this model system involved potent deletion of activated T cells and efficient suppression of inflammatory cytokine production. This effect was remarkably selective; etoposide did not exert a direct anti-inflammatory effect on macrophages or dendritic cells, and it did not cause deletion of quiescent naive or memory T cells. Finally, etoposide's immunomodulatory effects were similar in wild-type and perforin-deficient animals. Thus, etoposide treats HLH by selectively eliminating pathologic, activated T cells and may have usefulness as a novel immune modulator in a broad array of immunopathologic disorders. The Journal of Immunology, 2014, 192: 84-91.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 84-91 (8 pages)Journal (Volume, Issue Number)
Journal of Immunology (Volume 192, Issue 1)Publication milestones
- Published - 01/01/2014
Publication status
Published - 01/01/2014
ISSN
0022-1767Publication IDs
- Scopus: 84891071036
Publication metrics
Metrics
SciVal
FWCI
2.79
SciVal
Author count
6
SciVal
citations
86
SciVal
Paper percentile
97
SciVal
Top percentile
5
Fractional count
1
Fractional count
0.17
Fractional count
5
Fractional count
0.83
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Citation count
188
Captures
89
